Immix Biopharma, Inc. (IMMX) Financial Statements
Free cash flow over the same period: -$39.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMMXImmix Biopharma, Inc.Follow IMMX — free
—
Price chart with a free account
- Market cap
- 583.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 0.1 | 4.2 | 8.7 | 11.3 | 16.3 | 21.6 | |
| Operating income | -1.4 | -8.2 | -16.1 | -22.7 | -30.0 | -41.8 | |
| Pre-tax income | -24.4 | -8.2 | -15.6 | -21.7 | -29.4 | -39.9 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -24.4 | -8.2 | -15.4 | -21.6 | -29.4 | -39.9 | |
| Diluted EPS ($) | -6.64 | — | -0.89 | -0.76 | -0.89 | -0.62 | |
| Diluted shares (mn) | — | — | 17.3 | 28.3 | 33.0 | — |
USD millions · SEC XBRL
Immix Biopharma, Inc. — questions
- What is Immix Biopharma, Inc.'s net income?
- -$39.9M over the twelve months to 2026-06-30.
- What is Immix Biopharma, Inc.'s free cash flow?
- -$39.1M over the twelve months to 2026-06-30.
- What are Immix Biopharma, Inc.'s diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from Immix Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.